ARYA Sciences Acquisition Corp. IMTX 深 沪
已收盘 10-24 16:00:00 美东时间
10.18
0.000
0.00%
华盛通- 最 高10.44
- 今 开10.29
- 成交量 28.01万股
- 最 低 10.15
- 昨 收 10.18
- 总市值 12.42亿
- 52周最高 11.25
- 市盈率 静 66.06
- 换手率 0.23%
- 52周最低 3.30
- 委 比 -36.89%
- 总股本 1.22亿
- 历史最高 18.42
- 量 比 0.36
- 振 幅 2.85%
- 历史最低 3.30
- 每 手 1
- 风险率 1.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immatics Presents Updated Data From 16 Patients With Metastatic Uveal Melanoma Treated With Anzu-Cel PRAME Cell Therapy At ESMO 2025 Presidential Symposium
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show strong clinical benefit with more matureOne-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to sho
10-20 22:32
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
The Phase 1b trial of anzu-cel PRAME cell therapy in 16 patients with metastatic uveal melanoma shows strong clinical benefit, including a 67% confirmed objective response rate, median duration of response of 11.0 months, median progression-free survival of 8.5 months, and median overall survival not reached at 14.3 months. The therapy demonstrated favorable tolerability with manageable cytokine release syndrome (CRS), primarily Grade 1 or 2. Ant...
10-20 14:30
Immatics appoints industry veteran as CFO
Immatics N.V. (NASDAQ:IMTX) has appointed Venkat Ramanan as chief financial officer, effective immediately. Ramanan brings 25+ years of biopharma finance experience, with leadership roles at Seagen, G...
10-01 20:14
Immatics Appoints New CFO to Drive PRAME Therapy Commercialization
Immatics ( ($IMTX) ) has shared an announcement. On October 1, 2025, Immatics N...
10-01 19:49
Immatics Appoints Venkat Ramanan as Chief Financial Officer
Immatics N.V. announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, to succeed Arnd Christ. With over 25 years of experience in the biopharmaceutical industry, Ramanan will support the company's advancement of its PRAME franchise and commercialization of anzu-cel for patients with metastatic melanoma.
10-01 11:00
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
Guggenheim Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $16
Guggenheim analyst Paul Jeng initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating and announces Price Target of $16.
09-18 21:04
Immatics N.V. Reports Q2 2025 Financial Results
Immatics N.V. ( ($IMTX) ) has released its Q2 earnings. Here is a breakdown of ...
08-20 11:58
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the S&P 500 futures fallin...
08-19 18:21
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Results from the Phase 1b trial of IMA203 PRAME cell therapy in 33 heavily pretreated metastatic melanoma patients show favorable tolerability and durable clinical activity, with a confirmed ORR of 56%, mDOR of 12.1 months, mPFS of 6.1 months, and mOS of 15.9 months. Subgroup analyses demonstrate strong responses in both cutaneous (cORR 50%) and uveal melanoma (cORR 67%). These findings support the ongoing SUPRAME Phase 3 trial and highlight Imma...
05-31 12:00
